ZymoGenetics out-licenses eight preclinical compounds

ZymoGenetics Inc. (NASDAQ:ZGEN) granted Seattle Life Sciences (Seattle, Wash.) exclusive, worldwide rights to eight preclinical compounds outside of ZymoGenetics' core focus of immunology. Seattle Life Sciences, a newly formed company, said potential indications for the compounds include cancer, kidney and liver fibrosis, and wound repair. ZymoGenetics is eligible to receive undisclosed milestones and royalties. It also is entitled to an equity interest in Seattle Life in connection with Seattle Life obtaining venture capital financing. ...